Search results
1 maj 1998 · Male mice were treated with PGG-Glucan (Betafectin ®; Alpha-Beta Technology, Inc.; Worcester, MA), recombinant human G-CSF (Amgen; Thousand Oaks, CA) or pyrogen-free saline (McGaw, Inc.; Irvine, CA). PGG-Glucan was administered i.v. at single doses ranging from 0.5 mg/kg to 16 mg/kg.
PGG beta glucan at doses up to 6 mg/kg was tolerated in clinical trials in combination regimens including cetuximab or bevacizumab in treatment of colon and non-small cell lung cancer (Imprime PPG Investigators Brochure).
27 maj 2024 · Also, Pan et al. described an increase in TNF-α and IL-6 in septic individuals treated with β-glucans (dose of 500 µg). The varied results observed for glucans on IL-6 may be due their different doses in the studies.
This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days.
Patients in treatment groups were administered PGG glucan at a dose of 0.5 mg/kg or 1.0 mg/kg preoperatively and three times postoperatively. Results showed that there was no difference in severe infections and mortality between treatment and placebo groups.
An international multicenter, randomized, double-blind, placebo-controlled study showed a dose-dependent response of PGG-glucan against postoperative infections. β-Glucans are suggested to play an important role in the development of respiratory and organic dust-related diseases.
16 lis 2012 · The starting dose level of PGG beta glucan was 1 mg/kg, 2 nd dose level was 2 mg/kg and the 3 rd dose level 4 mg/kg. Subcutaneous ALM therapy started on day 3 with daily dose escalation (3 – 10 – 30 mg) and then 30 mg Mon-Wed-Friday for 4 weeks.
